AI pathology aid developer Medmain, a Kyushu Universty-aligned startup, will use the capital to support international expansion.
Medmain, a Japan-based pathology assistant software developer aligned to Kyushu University, has secured ¥1.1bn ($10.3m) from investors including IHW Group, operator of medical university International University of Health and Welfare, The Bridge reported on Wednesday.
Tokyo Institute of Technology’s Innovations and Future Creation also took part, as did health system Fukuoka Wajiro Hospital Group, telecoms group SoftBank’s Deepcore fund, consultancy Dogan’s investment arm Dogan Beta, QTnet, Hike Ventures and unnamed angel investors.
Hike Ventures leveraged a special purpose vehicle to arrange the funding, which The Bridge suggested was a series A round.
Founded in 2018, Medmain has built software and hardware to support pathology, the branch of medicine concerned with investigating tissues extracted from the patient to confirm a medical diagnosis.
Pathologists employ the software to remotely investigate digital scans, and receive image recognition-driven suggestions that improve as more cases are added to its database.
Medmain…
